Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
Joshua Rosenblat
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07569198CT.gov Ketamine With Dialectical Behavioural Therapy (DBT) for Suicidality in Individuals With Treatment-Resistant Depression and Borderline Personality Disorder (KET-DBT) | — | Not Yet Recruiting | — | — | — |
NCT07262008CT.gov Sustained Mood Improvement With Laughing Gas Exposure | — | Not Yet Recruiting | — | — | — |
NCT07227454CT.gov A Study to Evaluate the Efficacy and Safety of Esketamine for Reduction of Symptoms of Major Depressive Disorder | — | Recruiting | — | — | — |
NCT06752759CT.gov Nebulized Ketamine for the Treatment of Major Depressive Disorder | — | Recruiting | — | — | — |
NCT06228391CT.gov Ketamine Treatment for PTSD and MDD in TBI | — | Not Yet Recruiting | — | — | — |
NCT05625555CT.gov Predictors of Intravenous Ketamine Response in TRD | — | Active Not Recruiting | — | — | — |
NCT06480500CT.gov i-CBT and IV Ketamine for Suicidality in Treatment-Resistant Depression: A Randomized, Midazolam-Controlled Clinical Trial | — | Recruiting | — | — | — |
NCT05528718CT.gov SMILE Trial - Imaging Sub-Study | — | Completed | — | — | — |
NCT05046184CT.gov Elucidating the Neurocircuitry of Irritability With High-Field Neuroimaging to Identify Novel Therapeutic Targets | — | Completed | — | — | — |
NCT05045378CT.gov Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression | — | Completed | — | — | — |
Show 19 more trialsShow fewer
NCT04957368CT.gov Sustained Mood Improvement With Laughing Gas Exposure: A Randomized Controlled Pilot Trial | — | Completed | — | — | — |
NCT05870501CT.gov Synaptic Imaging and Network Activity in Treatment Resistant Depression | — | Completed | — | — | — |
NCT04939649CT.gov Ketamine As an Adjunctive Therapy for Major Depression (2) | — | Completed | — | — | — |
NCT05383313CT.gov Psilocybin Versus Ketamine in Treatment-Resistant Depression | — | Unknown | — | — | — |
NCT03666390CT.gov Using a Low Dose of Ketamine vs. Active Placebo in Treating Severe Depression and Suicide | — | Unknown | — | — | — |
NCT03185819CT.gov Study to Evaluate the Efficacy and Safety of 3 Fixed Doses of Intranasal Esketamine in Addition to Comprehensive Standard of Care for the Rapid Reduction of the Symptoms of Major Depressive Disorder, Including Suicidal Ideation, in Pediatric Participants Assessed to be at Imminent Risk for Suicide | — | Completed | — | — | — |
NCT03256162CT.gov Ketamine as an Adjunctive Therapy for Major Depression | — | Completed | — | — | — |
NCT02593643CT.gov Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression. | — | Completed | — | — | — |
NCT02661061CT.gov Ketamine for Relapse Prevention in Recurrent Depressive Disorder | — | Terminated | — | — | — |
NCT02579928CT.gov Ketamine Infusion for Adolescent Depression and Anxiety | — | Completed | — | — | — |
NCT02522377CT.gov Administration of Subanesthetic Dose of Ketamine and Electroconvulsive Treatment for Treatment Resistant Depression | — | Completed | — | — | — |
NCT02360280CT.gov Efficacy of Repeated Ketamine Infusions for Treatment-resistant Depression | — | Completed | — | — | — |
NCT02461927CT.gov Ketamine for the Rapid Treatment of Major Depressive Disorder and Alcohol Use Disorder | — | Completed | — | — | — |
NCT01920555CT.gov Double-Blind, Placebo-Controlled Trial of Ketamine Therapy in Treatment-Resistant Depression (TRD) | — | Completed | — | — | — |
NCT01944293CT.gov Ketamine for Suicidality in Bipolar Depression | — | Completed | — | — | — |
NCT01945047CT.gov Action of Ketamine in Treatment-Resistant Depression | — | Completed | — | — | — |
NCT01700829CT.gov Ketamine in the Treatment of Suicidal Depression | — | Completed | — | — | — |
NCT00952653CT.gov Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam | — | Completed | — | — | — |
NCT00768430CT.gov Optimization of IV Ketamine for Treatment Resistant Depression | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Major Depressive Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Midazolam (this asset) | Joshua Rosenblat | Approved | BB · 71 |
| Risperidone | Johns Hopkins University | P4 | BBB |
| Selegiline | Corium Innovations, Inc. | P4 | BBB |
| Edivoxetine | Eli Lilly and Company | P3 | BBB |
| Brexpiprazole | Nova Scotia Health Authority | P4 | BBB |
| Vortioxetine | Mayo Clinic | P4 | BBB |
| (1S,2R)-MILNACIPRAN | Allergan | P4 | BBB |
| Amitriptyline | e-Therapeutics PLC | P4 | BBB |
| Desvenlafaxine | Pfizer | P4 | BBB |
+42 more in the Major Depressive Disorder cohort
Other indications for Midazolam
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neuralgia | — | P4 | BBB · 75 |
| Gastrointestinal Stromal Tumor | — | P4 | BBB · 75 |
| Choledocholithiasis | — | P4 | BBB · 73 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Midazolam in Major Depressive Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/midazolam-major-depressive-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →